Indian Pharma Revenue to Grow 9-11% in FY24: Icra
By Rediff Money Desk, NEWDELHI Jan 04, 2024 20:16
Icra forecasts Indian pharma companies' revenue to grow 9-11% in FY24, driven by US market expansion and growth in domestic and emerging markets. Read more.
New Delhi, Jan 4 (PTI) Revenue of 25 leading domestic pharmaceutical companies is expected to grow 9-11 per cent in the current fiscal year, as per Icra.
The projected revenue growth in 2023-24 will be primarily supported by 11-13 per cent expansion in the US market and 7-9 per cent growth in the domestic market, while revenues from the European market and emerging markets are expected to rise 11-13 per cent and 13-15 per cent, respectively, the rating agency said in a statement.
"Icra expects the revenues of a sample set of 25 Indian pharmaceutical companies (which account for 60 per cent of the overall revenues of the Indian pharmaceutical industry) to expand by 9-11 per cent in FY24, post a year-on-year growth of 10 per cent in FY23," it noted.
Icra said it foresees research and development expenses for its sample set of companies to stabilise at 6.5-7 per cent of their revenues as they will optimise spending, focusing more on complex molecules and specialty products against plain vanilla generics.
The US has always been a key market for most leading Indian pharmaceutical companies, accounting for a sizeable share of their revenues.
However, the share of revenues from the US market for Icra's sample set of companies declined to 35 per cent in FY22 as compared with 40 per cent in FY20, owing to consistent pricing pressure, lack of major blockbuster products going off-patent and increased regulatory scrutiny in recent years, the rating agency said.
Nonetheless, with the easing of pricing pressure, significant new launches, and shortages of some products, the same increased to 37 per cent in FY23 and 38 per cent in the first half of FY24, it added.
The projected revenue growth in 2023-24 will be primarily supported by 11-13 per cent expansion in the US market and 7-9 per cent growth in the domestic market, while revenues from the European market and emerging markets are expected to rise 11-13 per cent and 13-15 per cent, respectively, the rating agency said in a statement.
"Icra expects the revenues of a sample set of 25 Indian pharmaceutical companies (which account for 60 per cent of the overall revenues of the Indian pharmaceutical industry) to expand by 9-11 per cent in FY24, post a year-on-year growth of 10 per cent in FY23," it noted.
Icra said it foresees research and development expenses for its sample set of companies to stabilise at 6.5-7 per cent of their revenues as they will optimise spending, focusing more on complex molecules and specialty products against plain vanilla generics.
The US has always been a key market for most leading Indian pharmaceutical companies, accounting for a sizeable share of their revenues.
However, the share of revenues from the US market for Icra's sample set of companies declined to 35 per cent in FY22 as compared with 40 per cent in FY20, owing to consistent pricing pressure, lack of major blockbuster products going off-patent and increased regulatory scrutiny in recent years, the rating agency said.
Nonetheless, with the easing of pricing pressure, significant new launches, and shortages of some products, the same increased to 37 per cent in FY23 and 38 per cent in the first half of FY24, it added.
Read More On:
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 8.36 ( -0.12)
- 56233421
- Srestha Finvest
- 0.60 (+ 3.45)
- 40360444
- Standard Capital
- 0.99 ( -1.00)
- 23259568
- AvanceTechnologies
- 0.92 ( 0.00)
- 16468235
- Gujarat Natural Res
- 24.73 (+ 4.13)
- 12245243
MORE NEWS
Bihar Food Processing Investors' Meet: Chirag...
Bihar hosts a food processing investor meet on December 2nd, showcasing its potential...
India's Coal Production Rises 7.2% in November
India's coal production increased by 7.2% in November 2024 to 90.62 million tonnes,...
Petrol & Diesel Sales Surge on Festive Demand
India's petrol and diesel consumption rebounded in November, driven by festive season...